October 14, 2022 Cancer “vaccines” enter the neoantigen stage Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
August 31, 2017 Corporate venture firms – dedicated followers of fashion? Eagerly pursuing all the latest fads and trends.
September 02, 2016 Snippet roundup: Tecentriq gets lung cancer win, Enbrel biosimilar patent dance intensifies
